In general, the management approach to a patient with cardiac amyloidosis involves treatment of the underlying cause (chemotherapy for AL, TTR‐directed therapies for ATTR) and concurrent management of heart failure, arrhythmia, and accompanying symptoms [19]. The gene discussed is TTR; the disease is cardiac arrhythmia.